Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Zilucoplan in Generalized Myasthenia Gravis
2024-512399-37-00Phase 3Completed
- Sponsor
- UCB
- Start
- Dec 2020
- Modality
- Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of zilucoplan in myasthenia gravis (MG), sponsored by UCB. Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs). Started Dec 2020; status: completed.
02
Drugs
zilucoplan
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2024-512399-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512399-37-00.